Asuragen Expanded QuantideX qPCR BCR-ABL Portfolio

Asuragen has launched a new CE-marked QuantideX qPCR BCR-ABL minor kit for identifying minor (e1a2) BCR-ABL fusion transcripts in patients with chronic myeloid leukemia. The new test joins the firm's existing FDA-cleared and CE-marked QuantideX qPCR BCR-ABL IS Kit that covers major (e13a2, e14a2) fusions.

The two kits can be combined in a streamlined and common workflow, and Asuragen said it is also expanding the capabilities of its QuantideX Reporter, analysis software, which accompanies the CE-marked QuantideX qPCR BCR-ABL IS Kit, to allow laboratories the ability to report CML patient disease burden on the International Scale after reviewing ABL1 copy number, in compliance with European LeukemiaNet guidelines.